Re: From NYT - Questioning a Cancer Drug That Costs $30,000 a Month
"Folotyn has not yet shown an effect on longevity. In the clinical trial that led to approval of the drug, 27 percent of the 109 patients experienced a reduction in tumor size. The reductions lasted a median of 9.4 months.
But considering all the patients in the trial, only 12 percent had a reduction in tumor size that lasted for more than 14 weeks. The trial did not compare Folotyn to another drug or a placebo."
WOW!!! Talk about backasswards.
fda had better approve Provenge.